Product logins

Find logins to all Clarivate products below.


Obesity / Overweight – Current Treatment – Treatment Algorithms: Claims Data Analysis – Obesity / Overweight (US)

As the prevalence of obesity rises, the demand for safe and effective treatments increases. Therapies mimicking GLP-1 and GIP peptides—hormones that regulate appetite and energy metabolism—have set new standards in weight-loss drugs. Led by Novo Nordisk’s Wegovy (semaglutide), these therapies are driving rapid growth of the obesity therapy market and are on a path to transform the therapeutic landscape. Wegovy and Eli Lilly’s Zepbound (tirzepatide) are the most advanced antiobesity therapies, offering significantly greater weight-loss efficacy than that of Novo Nordisk’s Saxenda. Older treatments such as phentermine, Contrave, Qsymia, and Xenical are also losing favor despite their lower costs. This report provides in-depth analysis and insight into how prescription weight-loss drugs are used to treat obesity and how medical practice is evolving.

Questions answered

  • What patient shares do key therapies and brands garner by line oftherapy in newly diagnosed obese/overweight patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed obese/ overweight patients?
  • How have the GLP-1 RA products been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of obese/overweight patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of obese/overweight patients are treated with monotherapy vs. combination therapy? What are the most used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Key drugs covered

Tirzepatide, semaglutide, liraglutide, phentermine + topiramate FDC, naltrexone + bupropion FDC, orlistat

Key analyses

  • Brand / therapy usage across patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flow

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Osteoarthritic Pain – Landscape & Forecast – Disease Landscape & Forecast (G7)
Osteoarthritic (OA) pain is prevalent, debilitating, and challenging to manage. Current treatments, including intra-articular agents, NSAIDs, antidepressants, opioids, and antiepileptic drugs, are…
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Psoriatic Arthritis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The psoriatic arthritis (PsA) treatment market is experiencing significant shifts with the introduction of newer targeted therapies, such as AbbVie’s Rinvoq and Skyrizi, and UCB’s bimekizumab…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Human Immunodeficiency Virus – Landscape & Forecast – Disease Landscape & Forecast (G7)
The HIV therapy market is undergoing significant transformation, driven by innovative ARVs and evolving treatment strategies. The market is crowded with many approved ARVs, including STRs such as…